Endocrine Cancer

ENDOCRINE CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

Biosimilars in Cancer Care: Insights From 2020 and Expectations for 2021

Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
NCI-MATCH Trial Identifies Actionable Alterations in More Than One-Third of Patients With Cancer

Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.
Reliability of Laboratory-Developed Tests Called Into Question

A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
How the Coronavirus Pandemic May Affect Cancer Clinical Trials

Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
The Twitter Effect on How Oncologists Conduct and Share Research

The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.

ENDOCRINE CANCER NEWS

FDA_accelerated approval

Gavreto Gets Accelerated Approval for RET-Altered Thyroid Cancers

December 3, 2020

The USPSTF stated that there was inadequate direct evidence for the benefits of screening.

RET Inhibitor Demonstrates Efficacy in RET-Altered Thyroid Cancer

September 2, 2020

FDA: Unacceptable NDMA Levels Identified in Certain Metformin ER Products

May 29, 2020

FDA_accelerated approval

Retevmo Gets Accelerated Approval for RET-Driven Lung, Thyroid Cancers

May 12, 2020

World Trade Center after 9/11 attack

Regular Medical Surveillance in World Trade Center Emergency Personnel May Explain Increased Rates of Thyroid Cancer

April 30, 2020

Next post in Endocrine Cancer

The USPSTF stated that there was inadequate direct evidence for the benefits of screening.

RET Inhibitor Demonstrates Efficacy in <i>RET</i>-Altered Thyroid Cancer